EssexBio

Essex-Bio Group

简繁 EN

COMPANY NEWS

Study Primary Endpoint Met in a Phase 3 Clinical Study of Bevacizumab EB12-20145P (HLX04-O) for the Treatment of Ophthalmic Diseases

2025.04.02

Essex Bio-Technology Reports Stellar 2024 Annual Results：Net Profit soars 11.6% to HK$ 307.2 Million, Dividend increases 33.3% Focuses on Strengthening R&D Capabilities and Expanding Market Access

2025.03.26

Preservative-free Unit-Dose Sodium Hyaluronate Eye Drops (0.3%) Obtained Approval from NMPA for Commercialisation in China

2024.09.13

Date

Title

2022-08-24

Essex Bio-Technology (1061.HK) 2022 Interim Results at a Glance

2022-08-23

Essex Bio-Technology Announces 2022 Interim Financial Results

2022-08-15

Essex Bio-Technology Included in "Forbes Asia's Best Under A Billion 2022”

2022-07-15

EssexBio awarded “2021 China Pharmaceutical Industry Top 100 Series List” and “2022 China Pharmaceutical Brands List”

2022-05-07

Essex Bio-Technology attends the 2022 GRC-FGF Conference, with two cutting-edge scientific research accepted by GRC

2022-04-29

Essex Bio-Technology Announces Upcoming Presentation at ARVO 2022 Annual Meeting

2022-04-19

First Patient in Australia Dosed in a Global Multicentre Phase 3 Clinical Study of Bevacizumab for treatment of Ophthalmic Diseases

2022-04-08

First Patient Dosed in a Global Multi-Centre Phase 3 Clinical Study of Bevacizumab EB12-20145P (HLX04-O) for treatment of Ophthalmic Diseases in the EU

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

ACCEPT